It is a dubious disease in the field of blood tumours, and clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of myeloma associated with gray platelet syndrome. The platform serves a team of domestic and foreign experts in the field of blood tumor in China. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.